Tags

Type your tag names separated by a space and hit enter

SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
Virology. 2008 Jun 20; 376(1):165-72.V

Abstract

A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-CoV S protein provides long-term protection of immunized mice from SARS-CoV infection (Kapadia, S.U., Rose, J. K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A., 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340(2), 174-82.). Because it is difficult to obtain regulatory approval of vaccine based on live viruses, we constructed a replication-defective single-cycle VSV vector in which we replaced the VSV glycoprotein (G) gene with the SARS-CoV S gene. The virus was only able to infect cells when pseudotyped with the VSV G protein. We measured the effectiveness of immunization with the single-cycle vaccine in mice. We found that the vaccine given intramuscularly induced a neutralizing antibody response to SARS-CoV that was approximately ten-fold greater than that required for the protection from SARS-CoV infection, and significantly greater than that generated by the replication-competent vector expressing SARS-CoV S protein given by the same route. Our results, along with earlier studies showing potent induction of T-cell responses by single-cycle vectors, indicate that these vectors are excellent alternatives to live-attenuated VSV.

Authors+Show Affiliations

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

18396306

Citation

Kapadia, Sagar U., et al. "SARS Vaccine Based On a Replication-defective Recombinant Vesicular Stomatitis Virus Is More Potent Than One Based On a Replication-competent Vector." Virology, vol. 376, no. 1, 2008, pp. 165-72.
Kapadia SU, Simon ID, Rose JK. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology. 2008;376(1):165-72.
Kapadia, S. U., Simon, I. D., & Rose, J. K. (2008). SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. Virology, 376(1), 165-72. https://doi.org/10.1016/j.virol.2008.03.002
Kapadia SU, Simon ID, Rose JK. SARS Vaccine Based On a Replication-defective Recombinant Vesicular Stomatitis Virus Is More Potent Than One Based On a Replication-competent Vector. Virology. 2008 Jun 20;376(1):165-72. PubMed PMID: 18396306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector. AU - Kapadia,Sagar U, AU - Simon,Ian D, AU - Rose,John K, Y1 - 2008/04/08/ PY - 2008/01/18/received PY - 2008/02/22/revised PY - 2008/03/04/accepted PY - 2008/4/9/pubmed PY - 2008/7/17/medline PY - 2008/4/9/entrez SP - 165 EP - 72 JF - Virology JO - Virology VL - 376 IS - 1 N2 - A SARS vaccine based on a live-attenuated vesicular stomatitis virus (VSV) recombinant expressing the SARS-CoV S protein provides long-term protection of immunized mice from SARS-CoV infection (Kapadia, S.U., Rose, J. K., Lamirande, E., Vogel, L., Subbarao, K., Roberts, A., 2005. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340(2), 174-82.). Because it is difficult to obtain regulatory approval of vaccine based on live viruses, we constructed a replication-defective single-cycle VSV vector in which we replaced the VSV glycoprotein (G) gene with the SARS-CoV S gene. The virus was only able to infect cells when pseudotyped with the VSV G protein. We measured the effectiveness of immunization with the single-cycle vaccine in mice. We found that the vaccine given intramuscularly induced a neutralizing antibody response to SARS-CoV that was approximately ten-fold greater than that required for the protection from SARS-CoV infection, and significantly greater than that generated by the replication-competent vector expressing SARS-CoV S protein given by the same route. Our results, along with earlier studies showing potent induction of T-cell responses by single-cycle vectors, indicate that these vectors are excellent alternatives to live-attenuated VSV. SN - 0042-6822 UR - https://www.unboundmedicine.com/medline/citation/18396306/SARS_vaccine_based_on_a_replication_defective_recombinant_vesicular_stomatitis_virus_is_more_potent_than_one_based_on_a_replication_competent_vector_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0042-6822(08)00173-6 DB - PRIME DP - Unbound Medicine ER -